Large B-cell Lymphoma Clinical Trials in Philadelphia, Pennsylvania

6 studies are recruiting for large b-cell lymphoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

   The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   65 in total

   Run by

   AstraZeneca

   See if you can join NCT06564038 on ClinicalTrials.gov

2. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

   This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ I…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   83 in total

   Run by

   Allogene Therapeutics

   See if you can join NCT06500273 on ClinicalTrials.gov

3. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

   This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University, Philadelphia, Pennsylvania

   Locations

   35 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05826535 on ClinicalTrials.gov

4. Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

   This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT07478848 on ClinicalTrials.gov

5. SynKIR-310 for Relapsed/Refractory B-NHL

   This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   5 in total

   Run by

   Verismo Therapeutics

   See if you can join NCT06544265 on ClinicalTrials.gov

6. BHB & CAR-T for Lymphomas

   The aim of this study is to assess the feasibility of β-hydroxybutyrate (BHB) supplementation in individuals who are receiving therapy for lymphoma with standard-of-care anti-CD19 CAR T-cells (CAR-T) to determine whether BHB supplementation is safe and tolerable in this patient population. Addition…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT06610344 on ClinicalTrials.gov